Cancer drug firm Alphamab jumps on HK debut, game developer XD climbs

XD

12/12/2019 04:59

** Shares of biopharmaceuticals company Alphamab Oncology
 9966.HK  trade as high as at HK$13.80 on debut, up 35.3% from
their Hong Kong IPO price of HK$10.2 apiece
    ** Stock is 4th most actively traded shares in late morning
trade 
    ** Alphamab Oncology, which specialises in development of
biologics for cancer therapy, has priced its Hong Kong IPO at
the top of the price range to raise HK$1.83 bln ($234 mln)
 urn:newsml:reuters.com:*:nL4N28G0RE
    ** Suzhou-based company offered 179.4 mln shares in Hong
Kong IPO, raising capital to fund key drugs development
programms and for developing new manufacturing and research
facilities
    ** Another new comer XD Inc  2400.HK  surges 10.8% from IPO
price to as high as HK$12.30 apiece on first day of trading
    ** The Shanghai-based mobile game developer offered 63.6 mln
shares at HK$11.10 each in Hong Kong IPO, raising HK$706 mln to
fund development of game-related technology, expanding game
publishing business and to finance acquisitions  urn:newsml:reuters.com:*:nL4N28F20J
    ** The Hong Kong Hang Seng sub-index tracking information
technology firms  .HSCIIT  climbs 1.5%
    ** The Hang Seng China enterprises index  .HSCE  gains 1.1%,
and the benchmark index  .HSI  rises 1.3%

 (Reuters Messaging: donny.kwok.thomsonreuters.com@reuters.net)